Case report: Fast disease progression during adjuvant therapy with anti-PD-1 in stage III melanoma patients

BackgroundStage III surgically resected melanoma is a disease at high risk of recurrence. Immune checkpoint inhibitors (ICIs) and the target therapy with BRAF and MEK inhibitors significantly changed the outcome of patients with metastatic melanoma and several studies have also shown their benefit i...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Francesca Romana Di Pietro, Sofia Verkhovskaia, Rosa Falcone, Giulia Poti, Maria Luigia Carbone, Maria Francesca Morelli, Albina Rita Zappalà, Roberto Morese, Zorika Christiana Di Rocco, Gabriele Piesco, Paolo Chesi, Cristina Maria Failla, Paolo Marchetti, Federica De Galitiis
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-08-01
Subjects:	melanoma adjuvant immunotherapy anti-PD-1 hyperprogression disease molecular profiling
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1437325/full